Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
Establishing Celsion GmbH allows Celsion’s management to focus solely on GEN-1, its DNA-mediated IL-12 immunotherapy currently in Phase I/II development for the treatment of advanced ovarian cancer, and PLACCINE™, its nucleic acid vaccine platform. In addition to clinical and regulatory advice, Celsion’s ongoing investment in ThermoDox® will be limited to providing clinical drug supply and modest financial support.
ThermoDox® is currently under investigator-sponsored development for several cancer indications, including:
- A Phase I study led by the
University Medical Center Utrechtin the Netherlandsto determine the safety, tolerability and feasibility of ThermoDox® in combination with Magnetic Resonance Guided High Intensity Focused Ultrasoundhyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer.
- A Phase I study led by
Oxford Universityin the UKto assess intravenous delivery of ThermoDox® in combination with High Intensity Focused Ultrasoundin pancreatic cancer.
- A clinical project at the
National Institutes of Healthto evaluate ThermoDox® plus the chemotherapy drug mitomycin in bladder cancer.
Commenting on his new role in leading
About Celsion Corporation
Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, statements relating to the offering and the use of proceeds therefrom, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting clinical trials; the need for
Executive Vice President and CFO
LHA Investor Relations
# # #
Source: Celsion CORP